|Bid||7.45 x 800|
|Ask||8.50 x 1100|
|Day's Range||7.63 - 7.63|
|52 Week Range||6.90 - 14.91|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.50|
- Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors
Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision. The company said the Phase 1 trial conducted by its research partner Oxurion NV evaluating the safety of a single injection of THR-149 at three ascending dose levels in 12 subjects met its goals. "These trial results represent additional human clinical data generated using Bicycles, a new therapeutic modality developed using our proprietary technology," said Kevin Lee, chief executive of Bicycle Therapeutics. Shares have fallen 13% in the last month through Friday. The company went public in late May at $14 a share.
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME). Activation of the PKal enzyme has been shown to increase retinal vascular permeability, microaneurysm and inflammation in DME. This Phase I open-label, multi-center, non-randomized trial evaluated the safety of a single intravitreal injection of THR-149 at three ascending dose levels in 12 subjects with visual impairment due to center-involved DME.
Biotech Bicycle Therapeutics PLC ADS fell 10.7% in their trading debut Thursday, shedding $1.50 in their first hour of trade. The company priced its initial public offering late Wednesday at $14, selling 4.3 million shares to raise $60.2 million. The stock is trading on Nasdaq, under the ticker symbol "BCYC." Proceeds of the deal will be used to fund research and development and for working capital and general corporate purposes.
Bicycle Therapeutics plc priced its initial public offering late Wednesday at $14 per American Depositary Share, selling 4.3 million shares to raise $60.2 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BCYC." Separately, Ideaya Biosciences priced its IPo at $10 a share, selling 5 million shares to raise $50 million. That stock will also start trading later Thursday, under the ticker symbol "IDYA."
Bicycle Therapeutics plc , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions....
Bicycle Therapeutics will issue 4.33 million American depository shares, with each ADS representing one ordinary share of the company, according to the S-1 the company filed May 13. The company expects to price the offering between $14 and $16 and list its ADRs on the Nasdaq under the ticker symbol BCYC. At the midpoint of the estimated price range, the IPO will fetch the company gross proceeds of $64.9 million.